Research programme: TGF-beta antagonists - GLYCODesign

Drug Profile

Research programme: TGF-beta antagonists - GLYCODesign

Alternative Names: TGF-beta antagonists research programme - GLYCODesign; Transforming growth factor-beta antagonists research programme - GLYCODesign

Latest Information Update: 20 Aug 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GLYCODesign; Nonindustrial source
  • Class
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Inflammation; Viral infections

Most Recent Events

  • 20 Aug 2002 Discontinued - Preclinical for Cancer in Canada (unspecified route)
  • 20 Aug 2002 Discontinued - Preclinical for Inflammation in Canada (unspecified route)
  • 20 Aug 2002 Discontinued - Preclinical for Viral infections in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top